)
Corline Biomedical (CLBIO) investor relations material
Corline Biomedical Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Q3 revenue was SEK 2.356M versus SEK 1.305M YoY; lower-than-expected orders drove a temporary sales slowdown and a net loss of SEK 4.774M.
Management sees growth from Kardium and new medical-device customers, targeting SEK ~200M revenue in 2030 from Kardium alone.
Financial highlights
Jan–Sep revenue was SEK 11.335M versus SEK 5.547M; net loss improved to SEK 8.711M from SEK 9.687M.
Q3 operating loss was SEK 4.052M versus SEK 3.359M; net loss was SEK 4.774M versus SEK 3.359M.
Q3 operating costs rose to SEK 6.440M from SEK 4.972M, reflecting higher raw-material and personnel costs, including consultants.
Cash and cash equivalents were SEK 29.869M at Sep 30, 2026, versus SEK 5.818M a year earlier; cash includes Kardium’s USD 1M loan.
Outlook and guidance
FY2026 revenue guidance is SEK 16M and EBITDA guidance is negative SEK 10M; Q4 sales are expected to return to H1 2026 levels.
FY2027 guidance is SEK 30M revenue with positive EBITDA, alongside a marginal cost increase versus 2026.
SEK ~200M revenue in 2030 is projected from the Kardium relationship alone, based on expected PFA growth and successful Globe product launch.
- Sales more than doubled in H1 2026, driven by Globe system expansion and strong cash flow.CLBIO
Q2 2026 - Record commercial sales and Kardium partnership drive growth and margin improvement.CLBIO
Q1 2026 - First US commercial use of CHS™ and strong financing set stage for 2026 growth.CLBIO
Q4 2025 - Breakthrough quarter with FDA approval, long-term deal, and capital raise set stage for growth.CLBIO
Q3 2025 - Growth depends on Kardium's US launch, with cost cuts improving results despite lower sales.CLBIO
Q2 2025 - Sharply reduced costs and strategic focus position Corline for growth and profitability by 2025.CLBIO
Q3 2024 - Revenue down, losses widened, but US launch and new projects drive future potential.CLBIO
Q2 2024 - Corline's Q1 2025 loss widens, but US market entry and strong clinical data drive optimism.CLBIO
Q1 2025 - 2024 saw heavy losses and restructuring, but Corline targets US growth with CHSTM-coated Globe®.CLBIO
Q4 2024
)
)
)
)
)
)
)
)